Goal of the analysis:
Prepare a comprehensive dossier that demonstrates the clinical, economic, and societal value of a medical device for submission to Health Technology Assessment agencies (for example, NICE in the UK, HAS in France, IQWiG in Germany) and payers. This aims to secure favorable reimbursement decisions and support broader market access.
Data required:
- Clinical evidence (randomized controlled trials, observational studies, meta-analyses)
- Economic evaluations (cost-effectiveness analyses, budget impact models)
- Patient-reported outcomes (quality-of-life data, utility scores)
- Epidemiological and disease burden data
- Competitor or comparator information (current standard of care)
- Real-world evidence (claims data, registries, or post-market surveillance findings)
- Regulatory approvals and device labeling details
Detailed step-by-step instruction on how to conduct the analysis:
- Define the scope and HTA requirements. Identify which agencies or payer organizations will review the dossier, understanding their specific guidelines, submission formats, and decision criteria.
- Gather comprehensive clinical data. Assemble all relevant clinical studies and real-world evidence that establish the device’s safety and efficacy. Classify the data by study design and level of evidence.
- Develop economic models. Build or adapt health economic models (for example, cost-effectiveness, budget impact) to illustrate the device’s value proposition under local market conditions.
- Analyze patient-centered outcomes. Ensure that quality-of-life measures and patient-reported outcomes are integrated to highlight the device’s impact on patient well-being.
- Compare with existing standards of care. Position your device against comparator technologies or treatments, focusing on clinical benefits, cost savings, or reduced resource utilization.
- Compile and structure the dossier. Organize content into clear sections (for example, clinical evidence, economic models, safety profile, patient perspectives), and follow each HTA body’s specified format.
- Conduct an internal peer review. Validate the accuracy and completeness of the dossier. Solicit feedback from cross-functional teams (regulatory, medical affairs, market access) and refine as needed.
- Finalize submission and plan follow-up. Submit the dossier according to HTA guidelines, and prepare to address requests for clarification or additional data during the review process.
Format of the output of analysis:
- A structured HTA dossier following the relevant agency’s template, including executive summary, clinical data synthesis, economic evaluation, and supporting appendices
- A summary table mapping key evidence to the specific HTA criteria or evaluation framework
- A presentation or slide deck highlighting the dossier’s main arguments for value and cost-effectiveness
- An internal review report documenting peer feedback, revisions, and final approval
How to interpret results:
- A well-prepared dossier that aligns with HTA requirements and demonstrates robust clinical and economic benefits can significantly improve reimbursement outcomes.
- Incomplete data, methodological flaws, or an unclear value proposition may lead to negative or provisional decisions, requiring additional evidence generation.
- HTA recommendations often influence other payers and stakeholders, creating a ripple effect for market access and device adoption.
Steps a company can take to improve on this measure:
- Engage early with HTA agencies or local payers to clarify evidence expectations and reduce uncertainties.
- Build multidisciplinary teams (clinical, health economics, regulatory) to ensure a comprehensive approach to dossier development.
- Conduct robust data collection strategies, including real-world evidence initiatives, to strengthen the clinical and economic narrative.
- Update and refine the dossier as new data emerges or HTA requirements change, maintaining ongoing compliance and relevance.
- Foster relationships with key opinion leaders and patient advocacy groups to support the device’s value story and real-world applicability.
